肿瘤细胞治疗研究
英文原题：CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas.
肿瘤坏死因子（TNF）受体超家族8受体CD30分子在霍奇金淋巴瘤和间变性大细胞淋巴瘤的所有肿瘤细胞中均有表达，但在正常外周淋巴组织中仅在一小部分大淋巴样细胞中弱表达。
肿瘤坏死因子（TNF）受体超家族成员8受体CD30表达于霍奇金淋巴瘤和间变性大细胞淋巴瘤的所有肿瘤细胞中，但在正常外周淋巴组织中，仅少量大型淋巴细胞亚群呈弱表达。因此，CD30是诊断和治疗CD30表达型淋巴瘤的重要靶点。本文介绍CD30分子的发现历程，以及CD30如何促进淋巴瘤更精准的诊断和分类。此外，文章还阐述抗CD30免疫疗法的开发过程，以及抗CD30-澳瑞他汀偶联物和抗CD30 CAR-T细胞治疗CD30表达型淋巴瘤的影响。
The tumor necrosis factor (TNF)-receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues. This makes this molecule an important target for the diagnosis and treatment of CD30-expressing lymphomas. We describe the road to the discovery of the CD30 molecule and the way CD30 has contributed to more precise diagnosis and classification of lymphomas. Moreover, we address how anti-CD30 immunotherapy was developed and the impact of the anti-CD30-auristatin conjugate and anti-CD30 CAR-T cells in treating CD30-expressing lymphomas.
MEMBER ACCOUNT
登录成功会直接打开下一页。
